RxDoctor Payments Data

Joan Duggan, MD

Infectious Disease · Toledo, OHNPI 1891780300

Payments from drug & device makers

What this record shows

This record is dominated by education: $127 of the $203 with a category attached, or 62.9%. 4 manufacturers reported payments, led by Janssen Products, LP at 48.9% of the total. Reporting peaked in 2021 at $127 and has fallen 69.1% since, to $39 in 2025. That places this record below the midpoint for infectious disease clinicians in OH, where the typical reported total is $232.

$203in general payments, 2019–2025

Across 5 payments — averaging $40.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Products, LP$99
  • Johnson & Johnson$47
  • Theratechnologies Inc.$39
  • Gilead$17
$167,885in research payments, 2019–2025

Across 53 payments — averaging $3167.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Viiv Healthcare Company$107K
  • Partner Therapeutics, Inc.$45K
  • GSK$15K

What the payments were for

  • Food & beverage$7537%
  • Education$12763%

General payments by program year

19
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Products, LP1$99
Johnson & Johnson(2 entities)2$47
Theratechnologies Inc.1$39
Gilead1$17

How this compares

$203 in reported general payments places this provider in the 45th percentile of 308 infectious disease providers in Ohio.

See all infectious disease providers in Ohio

Medicare billing

Part B allowed, 2024
$10,836
Medicare patients
86
Services billed
151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala414$1,577,554
TivicayDolutegravir Sodium121$271,329
DescovyEmtricitabine/Tenofov Alafenam114$243,003
DovatoDolutegravir Sodium/Lamivudine31$126,462
PrezcobixDarunavir/Cobicistat24$55,175
JulucaDolutegravir/Rilpivirine12$40,034
Isentress HdRaltegravir Potassium12$23,046
Darunavir11$18,205
DuleraMometasone/Formoterol11$4,276
Posaconazole13$3,705
Lamivudine11$3,537
Emtricitabine-Tenofovir DisopEmtricitabine/Tenofovir (Tdf)14$869
Ritonavir12$503
Omeprazole25$306
Atorvastatin Calcium94$267

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$17$1,820,557528 claims
Johnson & JohnsonPrezcobix$47$55,17524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 308 infectious disease providers in Ohio.

Other infectious disease in Toledo

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →